The design and molecular modeling of CNS drugs.
The medical need for new drugs to treat CNS disorders and their commercial potential is not in question, however, CNS drugs may require different pharmacokinetic and pharmacological profiles to peripherally acting compounds. The role of molecular modeling in both identifying and rationalizing the design of CNS compounds has led to the development of a powerful array of techniques. This review addresses a number of prominent issues for CNS drug discovery and describes highlights that provide some insights into the use of molecular modeling to define and enhance the pharmacological profile of novel compounds.
George
A
A
Cerebrus, Winnersh, Berkshire RG41 5UA, UK. A.George@cerebrus.co.uk